SynthesisBJS open2022
Sentinel lymph node biopsy in patients with ductal carcinoma in situ: systematic review and meta-analysis.
Synthesis in BJS open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- [Changes in the surgery and histopathology of sentinel lymph nodes for breast cancer at the Bács-Kiskun County Teaching Hospital (Kecskemét) - Experiences of nearly 30 years and 4000 operations.]Magyar onkologia · 2026Review
- Development of a Nomogram-Based Clinical Estimation Model for Pathological Upstaging in Patients With Preoperative Ductal Carcinoma In Situ.The Kaohsiung journal of medical sciences · 2026Article
- Optimal Surgical Margin After Breast-Conserving Surgery in Pure Ductal Carcinoma in Situ: Is a 1 mm Margin Sufficient? A Retrospective Single-Center Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Recurrence Patterns and Overtreatment in Pure DCIS: A Retrospective Clinical and Radiological Follow-Up Study.Journal of personalized medicine · 2026Article
- Multicenter development and external validation of clinical-radiomics models to predict surgically confirmed upstaging in biopsy-proven DCIS using DCE-MRI.Journal of applied clinical medical physics · 2026Article
- Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 1: Locoregional Therapy, Pathology, Radiology.European journal of breast health · 2026Article
- Evaluating the role of sentinel lymph node biopsy in cT1-2N0M0 breast cancer: a SEER-based study.Gland surgery · 2025Article
- Is axillary surgery still justified in DCIS diagnosed via vacuum-assisted biopsy?World journal of surgical oncology · 2025Article
- Utility of Surgical Axillary Staging in Microinvasive Ductal Carcinoma In Situ: A National Cancer Database Analysis.Annals of surgical oncology · 2025Article
- Retrospective comprehensive analysis of regional lymph node recurrence in breast cancer patients (REASON study).Journal of cancer research and clinical oncology · 2025Article
- Accuracy and Outcomes of Sentinel Lymph Node Biopsy in Male with Breast Cancer: A Narrative Review and Expert Opinion.Current oncology (Toronto, Ont.) · 2024Review
- Ductal Carcinoma In Situ (DCIS) and Microinvasive DCIS: Role of Surgery in Early Diagnosis of Breast Cancer.Healthcare (Basel, Switzerland) · 2023Review
- Article
- Ductal Carcinoma Arising in a Squamous Epithelial Inclusion Cyst within an Axillary Lymph Node: A Challenging Nodal Metastasis.Case reports in pathology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAxillary lymph node status remains the most powerful prognostic indicator in invasive breast cancer. Ductal carcinoma in situ (DCIS) is a non-invasive disease and does not spread to axillary lymph nodes. The presence of an invasive component to DCIS mandates nodal evaluation through sentinel lymph node biopsy (SLNB). Quantification of the necessity of upfront SLNB for DCIS requires investigation. The aim was to establish the likelihood of having a positive SLNB (SLNB+) for DCIS and to establish parameters predictive of SLNB+.
methodsA systematic review was performed as per the PRISMA guidelines. Prospective studies only were included. Characteristics predictive of SLNB+ were expressed as dichotomous variables and pooled as odds ratios (o.r.) and associated 95 per cent confidence intervals (c.i.) using the Mantel-Haenszel method.
resultsOverall, 16 studies including 4388 patients were included (mean patient age 54.8 (range 24 to 92) years). Of these, 72.5 per cent of patients underwent SLNB (3156 of 4356 patients) and 4.9 per cent had SLNB+ (153 of 3153 patients). The likelihood of having SLNB+ for DCIS was less than 1 per cent (o.r. <0.01, 95 per cent c.i. 0.00 to 0.01; P < 0.001, I2 = 93 per cent). Palpable DCIS (o.r. 2.01, 95 per cent c.i. 0.64 to 6.24; P = 0.230, I2 = 0 per cent), tumour necrosis (o.r. 3.84, 95 per cent c.i. 0.85 to 17.44; P = 0.080, I2 = 83 per cent), and grade 3 DCIS (o.r. 1.34, 95 per cent c.i. 0.80 to 2.23; P = 0.270, I2 = 0 per cent) all trended towards significance in predicting SLNB+.
conclusionWhile aggressive clinicopathological parameters may guide SLNB for patients with DCIS, the absolute and relative risk of SLNB+ for DCIS is less than 5 per cent and 1 per cent, respectively. Well-designed randomized controlled trials are required to establish fully the necessity of SLNB for patients diagnosed with DCIS. REGISTRATION NUMBER: CRD42021284194 (https://www.crd.york.ac.uk/prospero/).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.